Stay updated with breaking news from Nasdaq Stro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research report issued to clients and investors on Friday, RTT News reports. They presently have a $12.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 243.84% from the stock’s current […]
Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price […]
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...
Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price […]
Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) – Equities research analysts at HC Wainwright raised their FY2023 EPS estimates for Sutro Biopharma in a report issued on Tuesday, November 14th. HC Wainwright analyst A. Fein now expects that the company will earn ($2.94) per share for the year, up from their prior forecast of ($2.96). […]